
n 2022, FDA’s Draft Guidance on Diversity Plans and passage of the Food and Drug Omnibus Reform Act (FDORA) significantly changed the landscape for diversity and inclusion in clinical trials. In the below interview, Curavit President and Co-Founder Dave Hanaman and Clinical Research Business Development Manager Natalia Husby discuss Curavit’s new Inclusivity, Diversity, and Equity in Action (IDEA) service offering with DIA Scientific Programs Associate Director Tamei Elliott.
“When a sponsor comes to us with a study and they want to understand which populations might be affected, when it comes to the therapeutic area or when it comes to selecting sites whether virtual or hybrid, we look at census data to identify potential locations if they want to focus on a specific group that might be underrepresented in that field of study,” continued Husby. “We’ve been getting to know different community partners and diverse specialized organizations that focus on different groups of people, whether they’re rural communities, or ethnic or racially diverse communities. We recommend them to sponsors so they can better learn how to engage with these communities.”
Watch the interview below.